Lv11
70 积分 2024-04-15 加入
Disease modifying therapies in diabetes and endocrinology
7天前
已完结
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
7天前
已完结
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
11天前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
16天前
已完结
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
16天前
已完结
European expert consensus statement on therapeutic goals in Fabry disease
1个月前
已完结
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
1个月前
已完结
Long‐term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes
1个月前
已完结
Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus
1个月前
已完结
Obstructive sleep apnea and obesity: A review of epidemiology, pathophysiology and the effect of weight-loss treatments
3个月前
已完结
皖公网安备34019202002308
